PROCEPT BioRobotics Reports Revenue Increase

By Tamara Parker • Sunday, May 04 10:04 • Permanent Link

PROCEPT BioRobotics Corporation has recently released its 10-Q report, providing insights into the company's financial performance and operations. The company, headquartered in San Jose, California, focuses on developing transformative solutions in urology, specifically targeting benign prostatic hyperplasia (BPH) through its AquaBeam Robotic System and HYDROS Robotic System.

In the first quarter of 2025, PROCEPT BioRobotics reported revenue of $69.2 million, marking a significant increase from $44.5 million in the same period in 2024. The revenue growth was primarily driven by higher sales volumes of system sales, handpieces, other consumables, and service contracts, with the United States accounting for a substantial portion of the increase. The company's gross margin also improved to 64% in the first quarter of 2025, up from 56% in the same period in 2024.

The company's operating expenses also saw an uptick, with research and development expenses increasing by 25% to $16.4 million, and selling, general, and administrative expenses rising by 39% to $55.2 million in the first quarter of 2025 compared to the same period in 2024. Despite the increase in operating expenses, PROCEPT BioRobotics managed to narrow its net loss to $24.7 million in the first quarter of 2025, compared to a net loss of $26.0 million in the same period in 2024.

PROCEPT BioRobotics' revenue is primarily generated from the sales and rentals of its robotic systems, sales of single-use disposable handpieces, and related accessories. The company also derives revenue from service and repair, and extended service contracts with its existing customers. Notably, the United States accounted for 87% of the company's revenue, while revenue from outside the United States contributed 13% in the first quarter of 2025.

Looking ahead, the company aims to grow its install base of robotic systems, increase system utilization, and leverage favorable reimbursement and coverage decisions by third-party payors to further drive its revenue. Additionally, PROCEPT BioRobotics plans to invest in research and development to drive continuous improvements and innovation in its technologies.

The market has reacted to these announcements by moving the company's shares 5.2% to a price of $55.62. For the full picture, make sure to review PROCEPT BioRobotics's 10-Q report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.